Physician profile
Daniel Edmundowicz
NPI 1114990579
$1,354.82
in general payments reported to CMS, 2019-2025
10 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.63 · 2020: $27.04 · 2021: $16.68 · 2022: $123 · 2023: $432 · 2024: $167 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757 · Travel and Lodging: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.80 |
| Travel and Lodging | $367.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $426.48 | 2023-2025 | Avvigo Guidance System, Watchman Flx |
| Siemens Medical Solutions USA, INC. | $401.57 | 2024-2025 | Naeotom Alpha |
| Abbott Laboratories | $146.42 | 2023 | Xience Sierra |
| Novartis Pharmaceuticals Corporation | $119.77 | 2023 | |
| Medtronic, INC. | $72.39 | 2022 | |
| Medtronic Vascular, INC. | $64.63 | 2019 | |
| Novo Nordisk INC | $34.27 | 2021-2022 | |
| Amgen INC. | $32.55 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $29.70 | 2023 | Arcalyst |
| Csl Behring | $27.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Edmundowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.